Navigation Links
Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
Date:2/4/2008

ivately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's corporate headquarters is in Basel, Switzerland.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact:

Synosia Therapeutics

In Europe:

Julie Walters at Tudor Reilly

Tel: +44(0)20-7016-7714

Mobile +44(0)775-3626967

julie.walters@tudor-reilly.com

In US:

Michele Parisi at Tudor Reilly

Tel: +1-925-864-5028

michele.parisi@tudor-reilly.com


'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
2. Synosia Therapeutics Announces Appointment of Chief Business Officer
3. Taligen Therapeutics Secures Series B Financing
4. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
6. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
9. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
11. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Worth, Texas (PRWEB) May 29, 2015 Translation ... grow. This is for a good reason--if used in a ... wonders for the offering of a business product or service ... which translation can have a positive effect on a company's ... or service that anyone in the world can use, why ...
(Date:5/28/2015)... 2015 Research and ... addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... report deals with therapeutic drug monitoring, a ... care by monitoring drug levels in the ...
(Date:5/28/2015)... , May 28, 2015 ... ) has announced the addition of ... - Technologies, Markets and Companies"  to ... ,This report describes and evaluates animal ... medicine and pharmaceuticals as well as ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ... Genetics Market by Products, by Testing services - Global ... The global animal genetics market is estimated to ... at a CAGR of 8-9% during the forecast period ... mainly driven by increasing animal protein consumption, increasing adoption ...
Breaking Biology Technology:Three Ways Translation Can Help Businesses Grow 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2
... ... , ... October 19, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical ... Medicine, Academy of Sciences of the Czech Republic, to study the effects of air ...
... Inc., today announced that the U.S. Food and Drug ... for the first 15 monoclonal antibodies in its proprietary ... use by blood donor centers, reference laboratories, and hospitals ... was formed earlier this year to directly commercialize its ...
... 17 UCB today announced data that showed rapid ... fatigue of rheumatoid arthritis (RA) as early as the ... damage (seen at week 24) following treatment with Cimzia® ... to 100 weeks. Cimzia® is approved for the treatment ...
Cached Biology Technology:Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... MADISON People get type 2 diabetes. So do cats. ... in the shape of proteins protect some and endanger others. ... it only differs a little bit from species to species," ... mammals that get type 2 diabetes, their amylin proteins aggregate ...
... Energy is making good on the second phase of a plant ... by Dr. Joshua Yuan, Texas A&M AgriLife Research plant pathologist., ... Yuan, who was granted $1.8 million for Phase I by the ... source., The scientist said his research is moving ahead so quickly ...
... the Earth has reached the limits of its biophysical ... and social norms relating to material production and consumption ... functioning of our planet,s life support systems. ... pivotal role to play in this transition. This timely ...
Cached Biology News:New look identifies crucial clumping of diabetes-causing proteins 2Plant fuel project moves to second phase under US Energy Department grant 2